(Adnkronos) - “Tra le nuove offerte che abbiamo a disposizione merita grandissima attenzione il vaccino contro l’Rsv. Siamo in un periodo di difficoltà economiche, per cui Nitag si è preso un po' di tempo per fare approfondimenti e analizzare quali possono essere gli approcci vaccinali migliori anche nei fragili e negli anziani”. Cosi Carlo Signorelli, presidente Nitag al Forum Prevenzione vaccinale dell’anziano e del fragile al Forum Prevenzione vaccinale dell’anziano e del fragile presso il Ministero della Salute.
Category
🗞
NewsTranscript
00:00The syncytial respiratory virus is an infection that, based on the data that we see, in infancy
00:11with greater certainty and with more solid data, in the elderly, in the frail, with data
00:19that still deserve a deepening, is responsible for an important part of the viruses transmitted
00:26by air and therefore absolutely deserves a great deal of attention, because in the past
00:33diagnoses were not done.
00:35I believe that among the new vaccine offers in discussion, and at the moment the Commission
00:42is also talking about it, which I have the honor to chair, which is the NITAG, there is the
00:48question of the offer to certain categories, I would say elderly and frail, of the vaccine
00:55against the syncytial respiratory virus.
00:57We are in a moment of great economic difficulties, so at this moment NITAG has taken some time
01:06to do some research and above all to analyze exactly what is the Barnell disease, that is,
01:14what is the real spread of the infection by the syncytial respiratory virus in the elderly
01:20and what can be the best vaccine approaches.
01:26Vaccine policies always offer new opportunities that the scientific world must evaluate with
01:32conscience and with absolute impartiality.
01:35This summer we have made three proposals, including monoclonal for RSV in the child,
01:42anti-meningo in adolescence, the discussion is in progress.
01:47We also take into account that studies are accumulating because they are vaccines that
01:52have been around for a very short time, so another topic of discussion is whether there
01:57will be a need for a call or not, which from the organizational point of view and also
02:02from the economic point of view is a fairly important fact.
02:07Studies are coming, results are coming, it is a dynamic process that we are analyzing.